After hospitalization for heart failure, many patients live with a diffuse fear: that of returning to the emergency room, of sudden shortness of breath, of the heart failing again. In this fragile moment, between medical surveillance and return to daily life, a French study opens up a rare perspective: that of monitoring capable not only of preventing complications, but also of reducing the risk of death almost by half. Published in theEuropean Journal of Heart Failure and presented at the Heart Failure 2026 congress, the results of the TELESAT PRIOR-HF study could permanently change the way we view medical remote monitoring.
After the hospital, the dizziness of returning home
Heart failure is a serious chronic illness, often overlooked in its daily reality. The heart can no longer pump enough blood to meet the body’s needs. Little by little, shortness of breath, extreme fatigue, swollen legs and distressing nighttime awakenings appear.
Each year, nearly 170,000 people are hospitalized in France for this pathology. And for many, leaving hospital marks the start of a particularly critical period. The following weeks are those of maximum risk of relapse, rehospitalization or death.
It is precisely this very fragile population that the TELESAT PRIOR-HF team wanted to study. The researchers focused on 1,258 patients who had already been hospitalized for heart failure in the previous twelve months. All were monitored in more than 300 French hospitals using the Satelia Cardio remote monitoring device, in addition to usual care. They were compared to 2,321 patients benefiting only from standard monitoring.
The principle of this remote monitoring is based on regular remote monitoring: symptoms reported by the patient, early alerts, analysis of data by algorithms and medical intervention before severe decompensation occurs. A medicine that is less spectacular than an operation or a new drug, but which acts over the long term, as close as possible to patients’ daily lives. And the results are impressive.
Fewer deaths, fewer emergencies: figures that shake up cardiology
The study shows a 46% reduction in deaths from all causes in remotely monitored patients. A considerable reduction in a pathology where each aggravation can become brutal.
The researchers also observe:
- 15% fewer hospitalizations for heart failure;
- 32% fewer trips to the emergency room;
- 35% fewer admissions to intensive care.
Behind these statistics, there are episodes avoided: respiratory distress identified earlier, a worsening detected before it requires hospitalization, a patient reassured before the situation changes.
Professor Nicolas Girerd, cardiologist at Nancy University Hospital and co-author of the study, underlines the importance of these results:
“What this study highlights is particularly interesting: the use of remote monitoring is associated with lower mortality in the patients most at risk, that is to say those who have been hospitalized for heart failure. This result is observed without overall additional cost, suggesting economic neutrality despite prolonged patient survival. Given the size of the population studied and the magnitude of the association observed, this is an important message for public decision-makers, likely to support the deployment of these approaches.”.
The researchers also highlight an indicator particularly observed in medicine: the “Number Needed to Treat” (NNT), in other words the number of patients who must be treated to avoid death. Here, it is estimated at 6.2 over 30 months. A particularly low figure, therefore favorable, compared to certain reference therapies already widely used in heart failure.
This effectiveness also questions the very evolution of chronic medicine. Because in heart failure, the challenge is not only to treat an acute attack: it is to prevent it from returning.
Innovation without additional cost: the start of a change of model?
The other major lesson from TELESAT PRIOR-HF concerns public finances. In a health system under pressure, all innovation is now scrutinized through a central question: how much does it really cost? Here, researchers speak of “economic neutrality”. The costs linked to remote monitoring would be offset by the hospitalizations avoided from the first month of follow-up. At six, twelve and twenty-four months, no statistically significant difference was observed between the expenses of telemonitored patients and those of the control group.
In other words: better monitoring did not cost more. For Dr Nicolas Pagès, founder and CEO of Satelia, this demonstration profoundly changes the debate:
“We are demonstrating for the first time on this scale, using real-life French data, that an innovation can save lives without weighing on public finances. The debate is no longer about the cost of remote monitoring, it is now about the reasons why not all eligible patients benefit from it yet..
The study even puts forward a national projection: if 80% of patients hospitalized for heart failure benefited from remote monitoring upon discharge, between 8,500 and 9,000 deaths could be avoided each year in France.
These figures will naturally have to be confirmed and observed over time. The researchers themselves point out that science advances by progressive consolidation of data. But one thing is already clear: remote monitoring is no longer just an experimental technological tool. It is gradually becoming a new way of supporting chronic illnesses, more continuous, more anticipatory and sometimes more reassuring for patients who live with the permanent fear of relapse.
In the corridors of cardiology departments, this perspective is already changing something. Not the promise of a miracle. But that, more concrete and perhaps more precious, of days saved without hospitalization, nights less anxious and lives prolonged without further burdening a weakened health system.